

				[2020]1086		
				A	40,100,000	
2020	7	10			400,108,752	
			40,100,000		360,008,752	
		12				3
				42,640,752		2021
7	12					
			A		400,108,752	
			40,100,000		360,008,752	

1

2

42,640,752

2021 7 12

1		17,485,776	4.37%	17,485,776	0
2		14,724,864	3.68%	14,724,864	0
3		10,430,112	2.61%	10,430,112	0
		42,640,752	10.66%	42,640,752	0

	1	268,066,000	0	268,066,000
	2	91,942,752	-42,640,752	49,302,000
		360,008,752	-42,640,752	317,368,000
	A	40,100,000	42,640,752	82,740,752
		40,100,000	42,640,752	82,740,752
		400,108,752	0	400,108,752

(本页无正文,为《中信建投证券股份有限公司关于天津海茵芦荻药业集团股份有限公司首次公开发行部分限售股份上市流通的核查意见》之签字盖章页)

